- AIM ImmunoTech signs Material Transfer and Research Agreement with the National Institute of Infectious Diseases (Japan) and Shionogi.
- Shinogi is a Leading Global Pharmaceutical Company.
- Agreement stipulates the testing an ampligen as a potential vaccine adjuvant for COVID-19.
AIM ImmunoTech has signed a material transfer and research agreement with Japan'....
Tags : AIM ImmunoTech, Shionogi, National Institute of Infectious Diseases, NIID, Ampligen, pharmaceuticals,